NVO catalysts
Catalysts and events linked to NVO, newest first.
NVO stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Viking raises $575 million to fund obesity phase 3 trials 2026-10-19 · Mixed | more funded obesity competition can affect future market-share and multiple assumptions | The source says key trial results are expected between 2027 and 2028. | Not recorded |
| Viking raises $575 million to fund obesity trials through 2028 2026-10-19 · Mixed | obesity-drug competition and category valuation | The source frames Viking within the obesity-drug competitive set that includes Novo Nordisk. | Not recorded |
| GLP-1 usage reaches 11% of US adults, shifting grocery and snack spend 2026-10-12 · Up | treatment expansion driving Wegovy revenue growth | Novo Nordisk experiences surging demand as GLP-1 user base reaches 11% of US adults. | Not recorded |
| Novo Nordisk Draws Valuation Trap Label as GLP-1 Competition Intensifies 2026-10-09 · Down | institutional multiple contraction following brokerage downgrade to value trap status | UBS analyst Michael Yee labeled Novo Nordisk a value trap, citing GLP-1 competition from Eli Lilly. | Not recorded |
| FDA Extends Review of Novo Nordisk Denecimig BLA Over Facility Remediation 2026-10-03 · Mixed | haemophilia A product launch timeline deferral | FDA extended denecimig review due to plant remediation; US launch planned for H1 2027. | Not recorded |
| FDA Extends Review of Novo Nordisk Denecimig BLA Over Facility Remediation Activities 2026-10-03 · Mixed | delayed US commercial cash flow timing into H1 2027 offset by intact clinical efficacy profile | Novo Nordisk official BLA update noting manufacturing remediation extension. | Not recorded |
| FDA Extends Novo Nordisk Denecimig BLA Review Over Facility Remediation 2026-10-03 · Down | commercial cash-flow deferral on delayed BLA approval | FDA extended denecimig BLA review with commercial US launch moved to H1 2027. | Not recorded |
| Novo Nordisk Warns on Growth Deceleration and Long-Term Ozempic Patent Expiry 2026-09-30 · Down | terminal valuation multiple compression on patent expiration risk | Novo Nordisk provided disappointing guidance to investors, forecasting a considerable slowdown in revenue growth and patent cliff for Ozempic. | Not recorded |
Do these developments change your position?
Review NVO alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-19Viking raises $575 million to fund obesity phase 3 trialsLLY NVO VKTX
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-12GLP-1 usage reaches 11% of US adults, shifting grocery and snack spendLLY MDLZ NVO PEP+0.49%
- 2026-10-12GLP-1 usage reaches 11% of US adults, shifting grocery and snack spendLLY MDLZ NVO PEP+0.49%
- 2026-10-09Novo Nordisk Draws Valuation Trap Label as GLP-1 Competition IntensifiesLLY NVO
- 2026-10-09Novo Nordisk Draws Valuation Trap Label as GLP-1 Competition IntensifiesLLY NVO
- 2026-10-03FDA Extends Novo Nordisk Denecimig BLA Review Over Facility RemediationNVO+0.59%
- 2026-10-03FDA Extends Novo Nordisk Denecimig BLA Review Over Facility RemediationNVO+0.59%
- 2026-10-03FDA Extends Novo Nordisk Denecimig BLA Review Over Facility RemediationNVO+0.59%
- 2026-10-03FDA Extends Review of Novo Nordisk Denecimig BLA Over Facility RemediationNVO+0.59%
- 2026-10-03FDA Extends Review of Novo Nordisk Denecimig BLA Over Facility Remediation ActivitiesNVO+0.59%
- 2026-09-30Novo Nordisk flags Ozempic patent cliff as Viking shows 16-19% loss — NVO GLP-1 multiple compressionNVO-1.35%
- 2026-09-30Novo Nordisk Cites Slowing Growth on Ozempic Patent Cliff ConcernsNVO-1.35%
- 2026-09-30Novo Nordisk Warns of Revenue Growth Deceleration on Patent ExpiryLLY NVO-1.35%
- 2026-09-30Novo Nordisk Cites Slowing Growth on Ozempic Patent Cliff ConcernsLLY NVO-1.35%
- 2026-09-30Novo Nordisk Warns of Revenue Growth Deceleration on Patent ExpiryLLY NVO-1.35%
- 2026-09-30Novo Nordisk Warns on Growth Deceleration and Long-Term Ozempic Patent ExpiryLLY NVO-1.35%
- 2026-09-28Eli Lilly Discontinues New GLP-1 Weight-Loss Candidate on EfficacyNVO-3.02%
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of SalesNVO-3.02%
- 2026-09-28Eli Lilly Discontinues New GLP-1 Weight-Loss Candidate on Efficacy → Bullish NVONVO-3.02%
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of SalesNVO-3.02%
- 2026-09-28Eli Lilly Discontinues New GLP-1 Weight-Loss Candidate on EfficacyNVO-3.02%
- 2026-09-28Eli Lilly Discontinues New GLP-1 Weight-Loss Candidate on EfficacyLLY NVO-3.02%
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Due to Subpar EfficacyLLY NVO-3.02%
- 2026-09-28Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise leadLLY NVO-3.02%
- 2026-09-28Eli Lilly Discontinues Experimental GLP-1 Candidate Following Efficacy ReviewLLY NVO-3.02%
- 2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy DataLLY NVO-3.02%
- 2026-09-27Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total RevenueLLY NVO-3.81%
- 2026-09-27Eli Lilly discontinues developmental obesity drug over unmet efficacy thresholdLLY NVO-3.81%
- 2026-09-27Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of RevenueLLY NVO-3.81%
- 2026-09-27Eli Lilly Discontinues Developmental GLP-1 Candidate Over Efficacy StandardsLLY NVO-3.81%
- 2026-09-27Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% RevenueLLY NVO-3.81%
- 2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli LillyLLY NVO-0.68%
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideLLY NVO RHHBY-0.68%
- 2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market PushLLY NVO-0.68%
- 2026-09-23Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share DefenseLLY NVO-0.68%
- 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist EnicepatideLLY NVO RHHBY-0.68%
- 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo ExpandsLLY NVO-10.27%
- 2026-09-18Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM CoverageLLY NVO-10.27%
- 2026-09-18Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formularyLLY NVO-10.27%
- 2026-09-18Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expandsLLY NVO-10.27%
- 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMsLLY NVO-10.27%
- 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverageLLY NVO-10.27%
- 2026-09-17Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against WegovyLLY NVO-10.58%
- 2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across DosesLLY NVO-1.24%
- 2026-09-01NexLife Expands Compounded GLP-1 Plans With Flat $119-$169 Monthly TiersLLY NVO-1.24%
- 2026-09-01NexLife Expands Compounded GLP-1 Pricing at $119-$169 Flat Monthly FeeLLY NVO-1.24%
- 2026-09-01NexLife Expands Compounded GLP-1 Plans With Flat $119-$169 Monthly TiersLLY NVO-1.24%
- 2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across DosesLLY NVO-1.24%
- 2026-08-31Novo Nordisk advances oral Wegovy and Vivani implant partnership in GLP-1 raceNVO-0.38%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.